THE001 (DPPG2-TSL-DOX)
Locally Advanced Soft Tissue Sarcoma (LA-STS)
Phase 1Active
Key Facts
About Thermosome
Thermosome is a clinical-stage biotechnology company developing a novel, target-agnostic tumor-targeting platform based on thermosensitive liposomes (DPPG2-TSLs). Its lead program, THE001, combines a liposomal doxorubicin formulation with regional hyperthermia to achieve up to 15-fold higher intra-tumoral drug concentration and stimulate an anti-tumor immune response. The company is targeting locally advanced soft tissue sarcoma (LA-STS) as its lead indication, with a Phase I dose escalation study set to conclude in summer 2025, aiming to replace the current standard-of-care doxorubicin with a more effective and potentially curative treatment.
View full company profile